Pathobiology of ovarian carcinomas
- PMID: 25556618
- PMCID: PMC4302089
- DOI: 10.5732/cjc.014.10273
Pathobiology of ovarian carcinomas
Abstract
Ovarian tumors comprise a heterogeneous group of lesions, displaying distinct tumor pathology and oncogenic potentiel. These tumors are subdivided into three main categories: epithelial, germ cell, and sex-cord stromal tumors. We report herein the newly described molecular abnormalities in epithelial ovarian cancers (carcinomas). Immunohistochemistry and molecular testing help pathologists to decipher the significant heterogeneity of this disease. Our better understanding of the molecular basis of ovarian carcinomas represents the first step in the development of targeted therapies in the near future.
Figures

Similar articles
-
[Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?].Bull Cancer. 2016 Mar;103(3):252-8. doi: 10.1016/j.bulcan.2015.12.005. Epub 2016 Feb 4. Bull Cancer. 2016. PMID: 26853278 Review. French.
-
[Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].Beijing Da Xue Xue Bao Yi Xue Ban. 2011 Feb 18;43(1):123-8. Beijing Da Xue Xue Bao Yi Xue Ban. 2011. PMID: 21321635 Chinese.
-
Histological classification of ovarian cancer.Med Electron Microsc. 2003 Mar;36(1):9-17. doi: 10.1007/s007950300002. Med Electron Microsc. 2003. PMID: 12658347 Review.
-
TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18. Exp Mol Pathol. 2013. PMID: 23965232
-
[Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].Zhonghua Fu Chan Ke Za Zhi. 2017 Oct 25;52(10):687-696. doi: 10.3760/cma.j.issn.0529-567X.2017.10.008. Zhonghua Fu Chan Ke Za Zhi. 2017. PMID: 29060967 Chinese.
Cited by
-
Role of different non-coding RNAs as ovarian cancer biomarkers.J Ovarian Res. 2022 Jun 17;15(1):72. doi: 10.1186/s13048-022-01002-3. J Ovarian Res. 2022. PMID: 35715825 Free PMC article. Review.
-
Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management.Semin Cancer Biol. 2021 Dec;77:99-109. doi: 10.1016/j.semcancer.2021.08.005. Epub 2021 Aug 18. Semin Cancer Biol. 2021. PMID: 34418576 Free PMC article. Review.
-
Small Non-Coding-RNA in Gynecological Malignancies.Cancers (Basel). 2021 Mar 3;13(5):1085. doi: 10.3390/cancers13051085. Cancers (Basel). 2021. PMID: 33802524 Free PMC article. Review.
-
Decreased risk of ovarian cancer associated with rs9898876 sex hormone-binding globulin gene variant.Mol Biol Rep. 2022 Jun;49(6):4537-4544. doi: 10.1007/s11033-022-07297-1. Epub 2022 Mar 11. Mol Biol Rep. 2022. PMID: 35277784
-
Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis.Int J Med Sci. 2022 Jan 1;19(2):233-241. doi: 10.7150/ijms.67027. eCollection 2022. Int J Med Sci. 2022. PMID: 35165509 Free PMC article.
References
-
- Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO classification of tumours of female reproductive organs. Lyon: IARC Press; 2014.
-
- Yanick J, Ries LG, Yates JW. Ovarian cancer in the elderly: an analysis of surveillance. J Obstet Gynecol. 1986;154:639–647. - PubMed
-
- Lauchlan SC. Metaplasia and neoplasias of the Müllerian epithelium. Histopathology. 1884;8:543–557. - PubMed
-
- Fathalla MF. Incessant ovulation—a factor in ovarian neoplasia. Lancet. 1971;2:163. - PubMed
-
- Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012;23(Suppl 10):111–117. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical